Skip to main content
Clinical Trials/NCT02233205
NCT02233205
Unknown
Phase 1

Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Liver Metastases From Gastrointestinal Tumors and Pancreatic Carcinoma

Peking University Cancer Hospital & Institute1 site in 1 country18 target enrollmentOctober 2014

Overview

Phase
Phase 1
Intervention
ultrasonic microbubbles
Conditions
Gastrointestinal Neoplasms
Sponsor
Peking University Cancer Hospital & Institute
Enrollment
18
Locations
1
Primary Endpoint
Number of Participants with Serious and Non-Serious Adverse Events
Last Updated
10 years ago

Overview

Brief Summary

Ultrasonic sonoporation can increase the release of chemotherapeutics, thus increasing the therapeutic effects. The main purpose is to identify the safety of combining ultrasonic microbubbles and chemotherapeutics to treat malignant neoplasms of hepatic metastases from alimentary system and pancreatic carcinoma.

Detailed Description

Ultrasonic sonoporation can increase the release of chemotherapeutics, thus increasing the therapeutic effects. 1. Main purpose 1. To identify the safety of combining ultrasonic microbubbles and chemotherapeutics to treat malignant neoplasms of hepatic metastases from alimentary system and pancreatic carcinoma. 2. To explore the largest mechanical index and ultrasonic treatment time which patients can endure. 2. Secondary purpose 1. To observe tumor clinical benefit rate (CR+PR+SD). 2. To evaluate the preliminary effect,such as time to failure(TTF), time to death(TTD)

Registry
clinicaltrials.gov
Start Date
October 2014
End Date
June 2016
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Peking University Cancer Hospital & Institute
Responsible Party
Principal Investigator
Principal Investigator

Kun Yan

chief director

Peking University Cancer Hospital & Institute

Eligibility Criteria

Inclusion Criteria

  • Pathological diagnosis of liver metastases from alimentary system and pancreatic carcinoma
  • Failed routine chemotherapy
  • Neoplasms can be evaluated by imaging

Exclusion Criteria

  • Have systematic chemotherapy in 2 weeks
  • Be allergic to ultrasonic microbubbles and chemotherapeutics
  • Uncontrolled high blood pressure, cardiovascular disease
  • Active bleeding
  • Have serious mental and psychological disease

Arms & Interventions

microbubbles & platinum and gemcitabine

In 30min after chemotherapy, inject ultrasonic microbubbles 1 ml once and inject 5 times in 20min and locate the ultrasonic probe on the lesion The chemotherapy of pancreatic is gemcitabine.The chemotherapy of liver metastases is oxaliplatin with taxol.

Intervention: ultrasonic microbubbles

microbubbles & platinum and gemcitabine

In 30min after chemotherapy, inject ultrasonic microbubbles 1 ml once and inject 5 times in 20min and locate the ultrasonic probe on the lesion The chemotherapy of pancreatic is gemcitabine.The chemotherapy of liver metastases is oxaliplatin with taxol.

Intervention: platinum and gemcitabine

Outcomes

Primary Outcomes

Number of Participants with Serious and Non-Serious Adverse Events

Time Frame: 1 month

Secondary Outcomes

  • Time to Disease Progression(one year)

Study Sites (1)

Loading locations...

Similar Trials